Aadi bioscience announces financial results and operational update for the first quarter 2023 and provides update on precision 1 tumor agnostic trial

Total 1q 2023 revenue on fyarro® sales of $5.9 million precision 1 tumor agnostic trial enrolling equally in tsc1 and tsc2 arms with more than 15 discreet tumor types represented interim analysis on 40 patients with appropriate follow-up in precision 1 trial expected by end of 2023 conference call to be held today at 8:30 am edt los angeles , may 10, 2023 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mtor pathway genes, today announced financial results for the first quarter of 2023 and provided an initial update on the tumor-agnostic precision 1 trial, a registration-directed phase 2 study of nab-sirolimus in patients with solid tumors with pathogenic inactivating alterations in tsc1 or tsc2 genes. "we are excited about the uptake of fyarro and its continued sales growth after our first year on the market and believe we are operating from a position of strength with solid cash balances into 2025," said scott giacobello, interim ceo and president and cfo of aadi.
AADI Ratings Summary
AADI Quant Ranking